Cargando…
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624604/ https://www.ncbi.nlm.nih.gov/pubmed/37735558 http://dx.doi.org/10.1038/s41375-023-02029-1 |
| _version_ | 1785130950206685184 |
|---|---|
| author | Kubasch, A. S. Peterlin, P. Cluzeau, T. Götze, K. S. Sockel, K. Teipel, R. Jentzsch, M. Attalah, H. Sebert, M. Chermat, F. Gloaguen, S. Puttrich, M. Cross, M. Schneider, M. Kayser, S. Schipp, D. Giagounidis, A. Tirado-Gonzalez, I. Descot, A. van de Loosdrecht, A. Weigert, A. Metzeler, K. H. Fenaux, P. Medyouf, H. Platzbecker, U. Ades, L. |
| author_facet | Kubasch, A. S. Peterlin, P. Cluzeau, T. Götze, K. S. Sockel, K. Teipel, R. Jentzsch, M. Attalah, H. Sebert, M. Chermat, F. Gloaguen, S. Puttrich, M. Cross, M. Schneider, M. Kayser, S. Schipp, D. Giagounidis, A. Tirado-Gonzalez, I. Descot, A. van de Loosdrecht, A. Weigert, A. Metzeler, K. H. Fenaux, P. Medyouf, H. Platzbecker, U. Ades, L. |
| author_sort | Kubasch, A. S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10624604 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106246042023-11-05 Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial Kubasch, A. S. Peterlin, P. Cluzeau, T. Götze, K. S. Sockel, K. Teipel, R. Jentzsch, M. Attalah, H. Sebert, M. Chermat, F. Gloaguen, S. Puttrich, M. Cross, M. Schneider, M. Kayser, S. Schipp, D. Giagounidis, A. Tirado-Gonzalez, I. Descot, A. van de Loosdrecht, A. Weigert, A. Metzeler, K. H. Fenaux, P. Medyouf, H. Platzbecker, U. Ades, L. Leukemia Letter Nature Publishing Group UK 2023-09-21 2023 /pmc/articles/PMC10624604/ /pubmed/37735558 http://dx.doi.org/10.1038/s41375-023-02029-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Kubasch, A. S. Peterlin, P. Cluzeau, T. Götze, K. S. Sockel, K. Teipel, R. Jentzsch, M. Attalah, H. Sebert, M. Chermat, F. Gloaguen, S. Puttrich, M. Cross, M. Schneider, M. Kayser, S. Schipp, D. Giagounidis, A. Tirado-Gonzalez, I. Descot, A. van de Loosdrecht, A. Weigert, A. Metzeler, K. H. Fenaux, P. Medyouf, H. Platzbecker, U. Ades, L. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title_full | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title_fullStr | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title_full_unstemmed | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title_short | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial |
| title_sort | efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the emsco phase ii bergamo trial |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624604/ https://www.ncbi.nlm.nih.gov/pubmed/37735558 http://dx.doi.org/10.1038/s41375-023-02029-1 |
| work_keys_str_mv | AT kubaschas efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT peterlinp efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT cluzeaut efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT gotzeks efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT sockelk efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT teipelr efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT jentzschm efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT attalahh efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT sebertm efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT chermatf efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT gloaguens efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT puttrichm efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT crossm efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT schneiderm efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT kaysers efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT schippd efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT giagounidisa efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT tiradogonzalezi efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT descota efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT vandeloosdrechta efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT weigerta efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT metzelerkh efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT fenauxp efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT medyoufh efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT platzbeckeru efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial AT adesl efficacyandsafetyofbemcentinibinpatientswithadvancedmyelodysplasticneoplasmsoracutemyeloidleukemiafailinghypomethylatingagentstheemscophaseiibergamotrial |